Setmelanotide pharma grade API is released in two route-specific grades: an oral-grade powder for tablet, capsule, and granule manufacture, and an injectable-grade powder with reduced bioburden and endotoxin control for parenteral solution or lyophilized product. The drug substance is the acetate salt of a synthetic cyclic octapeptide, CAS 920014-72-8, with molecular formula C₄₉H₆₈N₁₈O₉S₂ and molecular weight 1117.3 g/mol. The sequence is acetyl-L-arginyl-L-cysteinyl-D-alanyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-cysteinamide cyclic (2→7)-disulfide, a conformationally constrained α-melanocyte-stimulating hormone analogue. Manufacture is performed by solid-phase peptide synthesis followed by preparative reversed-phase high-performance liquid chromatography and lyophilisation. No compendial monograph for setmelanotide exists in USP–NF or Ph. Eur.; release specifications are therefore established under the synthetic peptide drug substance framework of ICH Q6A and confirmed against the manufacturer’s process capability and stability data. For injectable use, the approved commercial presentation is a solution for subcutaneous injection at 10 mg/mL; for oral solid dosage forms, no commercialised product exists, and published data for this specific configuration is limited. The product is a white to off-white lyophilized powder, and storage conditions are assigned by the manufacturer, with moisture protection and controlled low temperature typically required to reduce hydrolysis and aggregation.

What Release Specifications Apply to a Synthetic Cyclic Peptide API for Both Oral and Injectable Use?

Quality control for setmelanotide API combines peptide-specific chromatographic identity with universal safety tests differentiated by route. Because the molecule is a synthetic peptide, the release panel includes both product-related impurities such as deletion peptides, oxidation products, and disulfide isomers, and process-related impurities such as residual solvents and elemental impurities. Identity is confirmed by liquid chromatography–mass spectrometry peptide mapping after reductive alkylation or enzymatic digestion, with detection of molecular ions consistent with the theoretical monoisotopic mass. Assay and related peptide determinations are performed by reversed-phase high-performance liquid chromatography with ultraviolet detection at 220 nm, where peptide bonds absorb and allow detection of the parent peptide and peptide-related species. Water content is determined by Karl Fischer titration using Ph. Eur. 2.5.12; residual solvents by headspace gas chromatography under ICH Q3C; elemental impurities by inductively coupled plasma mass spectrometry under ICH Q3D. Acceptance limits are justified by process capability, toxicological risk assessment, and batch-to-batch variance rather than a compendial monograph. The table below summarises the analytical matrix.

Unlike the acylated GLP-1 receptor agonists semaglutide and liraglutide, setmelanotide occupies a different pharmacological class with a central melanocortin mechanism. Semaglutide and liraglutide have molecular weights above 3500 g/mol and reduce body weight primarily through appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion. Setmelanotide is smaller at 1117.3 g/mol and acts as an agonist at the melanocortin-4 receptor. In patients with proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency, MC4R signalling is impaired downstream of the leptin–POMC pathway; setmelanotide can restore signalling in the specific genetic obesity forms described in approved product information. The approved indication is not general obesity but chronic weight management for adults and paediatric patients aged 6 years and older with obesity due to these genetic conditions or Bardet-Biedl syndrome. The approved route is subcutaneous injection, not oral administration. Differences from other products therefore include a genetically selected patient population, a central MC4R mechanism, a labelled risk of skin hyperpigmentation and injection-site reactions, and a relatively small peptide structure with a single disulfide constraint. For tablet and capsule development, this distinction matters: the API is potent at milligram-range doses and requires contained handling; oral solid dose forms must overcome gastrointestinal peptidase activity and low epithelial permeability, whereas injectable solution bypasses first-pass metabolism and has defined subcutaneous pharmacokinetic behaviour.

Solid-Dose Handling: From Lyophilized Powder to Granule and Tablet

Following lyophilization, setmelanotide powder exhibits poor flow, low bulk density, and electrostatic adhesion. Flow behaviour assessed by Ph. Eur. 2.9.36 and bulk density by Ph. Eur. 2.9.34 are typical of peptide APIs recovered from freeze-drying. Direct compression is therefore not a suitable manufacturing route unless the API is first spray-dried onto a carrier or co-processed by non-aqueous wet granulation. Aqueous granulation may introduce hydrolytic degradation and should be avoided unless forced degradation studies demonstrate acceptable stability at the proposed granulation moisture range; published data for this specific configuration is limited. Dry granulation by roller compaction is often evaluated for low-dose peptide tablets because it avoids solvent exposure, but the brittleness of freeze-dried peptide aggregates can produce fines that segregate in subsequent tablet compression. Capsule filling is commonly assessed as a lower-shear alternative, using semi-automatic dosator or tamping pin equipment with pre-blended excipients to minimise segregation. The uniformity of dosage units should be verified according to USP <905> or Ph. Eur. 2.9.40, and dissolution performance, if an oral formulation is developed, should be evaluated under the apparatus and acceptance criteria of USP <711> or Ph. Eur. 2.9.3. Because the API is light- and moisture-sensitive, handling in relative humidity above 60% can increase water uptake and accelerate aggregation; therefore, processing areas are typically controlled at low relative humidity and product is stored in sealed intermediate bulk containers. The oral-grade API is not terminally sterilized and does not require bacterial endotoxin release limits, but microbial limits for non-sterile products apply to the drug product under Ph. Eur. 5.1.4 and USP <1111>.

When the Route Shifts from Subcutaneous to Oral, Formulation Requirements Do Not Transfer

For subcutaneous injection, the approved product is a solution at 10 mg/mL. The labelled starting dose for adults and paediatric patients aged 12 years and older is 2 mg once daily, increased after 2 weeks to 3 mg once daily if tolerated. The pharmacokinetic profile of this route is determined by subcutaneous absorption and central MC4R engagement. An oral tablet, capsule, or granule cannot assume the same excipient compatibility, dissolution, or stability profile. Peptide drugs of molecular weight above 1000 g/mol generally display low and variable oral bioavailability because of gastric acid hydrolysis, intestinal peptidase degradation, and paracellular transport constraints. Setmelanotide has molecular weight 1117.3 g/mol and a cyclic disulfide that may confer some stability relative to linear peptides, but this does not eliminate enzymatic cleavage at the peptide backbone. Formulation approaches such as enteric coating, permeation enhancers, protease inhibitors, or lipid nanoparticles would be required to improve oral absorption, and each excipient introduces additional safety and compatibility testing under ICH M3. In vitro permeability can be screened with Caco-2 or parallel artificial membrane permeability assays, but regulatory acceptance requires in vivo pharmacokinetic comparison. Published data for a specific oral setmelanotide configuration is limited; no clinical trial package has established bioequivalence or therapeutic equivalence for oral setmelanotide solid dosage forms.

Endotoxin and Subvisible Particulate Control Determines Injectable Grade

To meet injectable-grade requirements, setmelanotide API is not necessarily sterile at release, but it must exhibit low bioburden and low bacterial endotoxin so that sterile filtration or aseptic processing can be completed without excessive membrane fouling. The formulation is typically prepared as a solution for subcutaneous injection and filtered through a 0.22 µm sterilizing-grade membrane. Sterilization by moist heat is generally not applicable to setmelanotide because of peptide degradation at elevated temperature; therefore, aseptic filtration followed by aseptic fill is the common manufacturing route. Endotoxin release limits are derived from the maximum daily dose, body weight, and route-specific threshold using the K/M formula under USP <85> and Ph. Eur. 2.6.14. Subvisible particulate matter must meet compendial limits by light obscuration according to USP <788> and Ph. Eur. 2.9.19, and visible particles must be absent on inspection. The route-specific control matrix is summarised below.